[A21-97] Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 20.01.2022
Project no.:
A21-97
Commission:
Commission awarded on 21.07.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with locally advanced or metastatic basal cell carcinoma who were previously treated with a hedgehog signal pathway inhibitor and show disease progression or intolerance to it during this treatment
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-60 | Cemiplimab - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-98 | Cemiplimab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-161 | Cemiplimab (basal cell carcinoma) - Addendum to Commission A21-97 | Commission completed |
| A23-37 | Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-36 | Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-01-20 A G-BA decision was published.